Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen Licenses Gene-Delivery Technology from Cell Genesys

NEW YORK, Aug. 10 – Invitrogen has exclusively licensed lentiviral gene-delivery technology from Cell Genesys for use in gene-expression research and drug-target validation, the companies said on Friday. 

The agreement grants San Diego-based Invitrogen worldwide rights to sell kits, products, and services using the lentiviral-vector technology. In return, Invitrogen will pay Cell Genesys royalties on any sales, as well as a portion of fees generated from sublicensing the technology to companies applying the technology to commercial bioprocessing or in their own products.

Lentiviral gene delivery is one technique for modifying a cell or organism’s DNA by delivering genetic information directly into a cell’s nucleus. The method is particularly useful for gene expression and drug-target validation studies in non-dividing or slowly dividing cells, the companies said in a statement.

Cell Genesys, based in Foster City, Calif., is developing cancer vaccines and gene-therapy techniques for treating major diseases. For applications outside of this focus, the company is seeking partners to license its gene-delivery intellectual property.

Last week, Cell Genesys acquired Calydon, a Sunnyvale, Calif.-based biotechnology company focused on developing therapeutic products for cancer. Cell Genesys also holds a 10.5 percent stake in antibody manufacturer Abgenix, based in Fremont, Calif.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.